Type 2 diabetes
Conditions
Interventions
Mitiglinide calcium hydrate administration group
Sponsors
St.Marianna University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients are being treated with diet therapy and DPP-4 inhibitor, metformin for more than 8 weeks (56 days) prior to the start of the study. 2)HbA1c (NGSP) before clinical trial start is 7.0% or more and 9.0% or less. 3)Patients are not clinically problematic anemia. 4)over 20 years age 5)Out patient 6)Patients who provided written consent
Exclusion criteria
Exclusion criteria: 1) Patients with contraindications against the use of mitiglinide calcium hydrate tablets and mitiglinide calcium hydrate/voglibose combimation tablets based on their package inserts. 2) Patients who had taken sulfonylureas, GLP-1 receptor agonists,glinide,a-GI, SGLT-2 inhibitors, insulin within 8 weeks (56 days) before the start of the study 3) Excessive drinkers 4) Patients with severe diabetic microangiopathy 5) Patients with severe liver / kidney function decline 6) Patients with severe heart disease 7) Patients with severe hypertension combined 8) Patients with open surgery or previous bowel obstruction 9)Patients who were judged to be ineligible to be ineligible by the investigator or sub-investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HbA1c Comparison at16weeks,24 weeks from the start of administration | — |
Secondary
| Measure | Time frame |
|---|---|
| GA 1.5AG Fasting blood glucose Fasting insulin HOMA-R Serum CPR | — |
Countries
Japan
Contacts
Public ContactHiroyuki Kato
St.Marianna University School of Medicine Hospital Division of Endocrinology and Metabolism
Outcome results
None listed